The ability of Pierre Fabre to compete in the near term against oncology heavyweights like Novartis and Roche was key to selecting the French company to commercialize and further develop Array BioPharma's MEK inhibitor binimetinib and BRAF inhibitor encorafenib in Europe and emerging markets.
With the compounds suddenly divested to it earlier this year and Phase III clinical studies involving the two agents nearing completion, Array BioPharma needed to sign up marketing partners quickly,...